Phase II Study of Binimetinib and Encorafenib in Patients with Metastatic Pancreatic Cancer with a Somatic BRAF V600E Mutation
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of Binimetinib and Encorafenib in patients with metastatic pancreatic cancer with a somatic BRAF V600E mutation.
General Information
NCT#: NCT04390243
Study ID: ACCRU-GI-1907
Trial Phase: Phase II
Trial Sponsor: Academic and Community Cancer Research United
Therapies Used in This Trial: Binimetinib, Encorafenib